A phase 1 study evaluated the safety and tolerability of LJM716 in patients with HER2-positive breast cancer or gastric cancer, or with esophageal squamous cell carcinoma (ESCC) or squamous cell carcinoma of the head and neck (SCCHN) regardless of HER2 status [132]. The gene discussed is ERBB2; the disease is gastric cancer.